Immune modulation in organ allograft recipients by single or multiple donor bone marrow infusions by Rao, AS et al.
, , 
i 
I 
ELSEVIER 
Immune Modulation in Organ Allograft Recipients by Single or 
Multiple Donor Bone Marrow Infusions 
AS. Rao, R. Shapiro, R. Corry, F. Dodson, K. Abu-Elmagd, S. Pham, M. Jordan, S. Salgar, A Zeevi, 
C. Rastellini, L. Ostrowski, A Aitouche, R. Keenan, J. Reyes, B. Griffith, T.E. Starzl, and J.J. Fung 
THE discovery of persistent alloantigen (i.e .. chimerism) in the lymphoid and nonlymphoid tissues of successful 
long-term organ transplant recipients has prompted many 
to conclude that this phenomenon plays an important role 
in allograft acceptance.1•2 These findings have been corrob-
orated in experimental models of transplantation (Tx) 
tolerance.3 Although the precise phenotype of cells in-
volved in the induction of observed donor-specific tolerance 
(DST) is unclear. there exists overwhelming evidence sug-
gesting that perhaps immature dendritic cells. which are 
resident within the graft and known to migrate after Tx. 
modulate host anti-donor effector responses:~ As these cells 
are of bone marrow (BM) origin, it was rational to propose 
that perioperative donor BM infusion may augment this 
phenomenon with resultant salutary effect on patient and 
graft survivals. In 1992 we initiated a clinical trial involving 
perioperative infusion of unmodified BM cells obtained 
from the vertebral bodies of cadaveric donors into abdom-
inal and thoracic organ allograft recipients. An interim 
analysis of the outcome in these patients is reported at their 
most recent follow-up. 
MATERIALS AND METHODS 
Bone Marrow Augmentation 
To augment donor cell chimerism. a single dose of 3-5 x 10" 
unmodified donor BM cellslkg body weight was infused into 226 
nonconditioned primary allograft recipients. The mean recipient 
and donor age was 40 and 29 years. respectively, with follow-up 
ranglllg from 3 to 2023 days (933 :<:: 507 days). Additionally, since 
April 30. 1996. we have also accrued 39 organ recipients (liver n = 
6. kidney n = 19) into a concurrent protocol involving multiple 
sequential infusions of unmodified BM (1-2 x 108 cellslkg per day) 
from days 0 to 4 posttransplantation; the mean recipient age being 
45 :!:: 11 years. with a follow-up from 4 to 790 days. Organ recipients 
(n = 131) for whom BM was not available were monitored as 
controls. Immunosuppression was with tacrolimus and steroids. 
CellCept being administered to 53 study and 17 control patients. 
In Vitro Analysis 
Using procedures described previously.s the presence of donor cell 
chimerism (hy polymerase chain reaction [PCR]) and cellular 
immune response (by mixed leukocyte response [MLRJ) was 
serially determllled using the peripheral blood of the recipients. 
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RESULTS AND DISCUSSION 
The infusion of BM (both single and multiple) was safe and, 
except for 55 patients (21 %), all study patients have optimal 
graft function, none being lost to causes uniquely ascribed 
to ancillary BM infusion. Of the control patients, allografts 
in 31 (24%) have been lost during the course of follow-up. 
Mild to moderate acute cellular rejection was evidenced in 
158/251 (63%) study and 101/131 (77%) control patients. 
Mild. easily reversible graft-vs-host disease (GvHD) was 
witnessed in only 2/226 (1%) patients receiving single BM 
infusion. In contrast. fulminant GvHD was discerned in 
1/37 (3%) recipients of multiple BM infusions, exhorting an 
immediate discontinuation of this protocol. Owing to con-
comitant existence of refractory donor-type EBV+ post-
transplant lymphoproliferative disease (PTLD) this patient 
initially benefited from autologous lymphokine activated 
killer [LAK] cell therapy, eventually succumbing at day 147 
post-Tx. Among those at least 1 year post-Tx, a steroid-free 
existence has been achieved in 94 (53%) study and 39 
(40%) control patients. 
As reported previously, the presence of a higher inci-
dence of multiline age chimerism was confirmed in the 
peripheral blood of evaluable study (-95%) patients as 
compared to that of the control (-53%) patients. Further-
more, serial in vitro immunological monitoring revealed the 
presence of a relatively higher incidence of donor-specific 
hypo reactivity (DSH) in 57% of study (liver. lung, kidney) 
recipients as compared to that of controls (44%). Con-
versely, a relatively lower incidence of DSH was evidenced 
in both study and control heart and kidney + pancreas 
recipients. Although BM infusion is safe with incontrovert-
From the Section of Cellular Transplantation, Thomas E. Starzl 
Transplantation Institute, and the Departments of Surgery and 
Pathology, University of Pittsburgh Medical Center. Pittsburgh, 
Pennsylvania. 
This work was aided by Project Grant AI40329 from the 
National Institutes of Health, Bethesda. Maryland. 
Address reprint requests to Abdul S. Rao. MD. Thomas E. 
Starzl Transplantation Institute. E1545 Biomedical Science 
Tower. 200 Lothrop St, Pittsburgh, PA 15213. 
© 1999 by ElseVIer Science Inc. 
655 Avenue of the Americas, New York, NY 10010 
Transplantation Proceedmgs. 31 700-701 (1999) 
------ --------------------
SINGLE OR MULTIPLE BONE MARROW INFUSIONS 
ible evidence for augmentation of chimerism. its effect on 
allograft survival and on our ability to reduce or withdraw 
nonspecific immunosuppression is still indeterminate. It 
must be emphasized that. unlike that in rodents. a longer 
follow-up will be required in outbred species such as 
humans for the discernment of the beneficial effects of 
8M infusion. 
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